{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:31:40Z","timestamp":1793881900134,"version":"4.7.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Thelma Zo\u00e9gas Foundation for medical research","award":["91282"],"award-info":[{"award-number":["91282"]}]},{"name":"Swedish Government Research Grant","award":["ST ALF 2016-2018 and 2020-2022"],"award-info":[{"award-number":["ST ALF 2016-2018 and 2020-2022"]}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005390","name":"Alfred \u00d6sterlunds Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Heparin-binding protein (HBP) is a neutrophil-derived pro-inflammatory protein, an inducer of endothelial dysfunction and vascular permeability and a promising prognostic biomarker in sepsis. This exploratory study aims to describe the kinetics of plasma HBP during septic shock and investigate an association between repeated measures of HBP concentration and cardiovascular organ dysfunction severity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included patients at or above 18\u2009years with suspected septic shock on admission to the intensive care unit (ICU) during 2014 and 2016 to 2018. Plasma samples were collected from ICU admission and every 4\u2009h for 72\u2009h or until death or ICU discharge and batch analysed for HBP. Mean arterial blood pressure (MAP) and noradrenaline dose (NA dose) were recorded at each sampling time point, and systemic vascular resistance index (SVRI) was recorded when available from non-invasive monitoring. The association between HBP, NA dose, MAP and SVRI was assessed respectively using mixed-effects linear regression models. Procalcitonin (PCT) was used as a comparator.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 24 patients were included. The kinetics of plasma HBP was highly variable over time, with occasional &gt;2-fold increases and decreases in between 4-h measurements. Every 100\u2009ng\/mL increase in HBP corresponded to a 30% increase in NA dose in a crude model (95% CI 3 to 60%, <jats:italic>p<\/jats:italic> = 0.03, <jats:italic>n<\/jats:italic><jats:sub>obs<\/jats:sub> = 340), a 1.4-mmHg decrease in MAP in an adjusted model (95% CI \u2212 1 to \u2212 2.3\u2009mmHg, <jats:italic>p<\/jats:italic> = 0.04) or a 99 dyne s cm<jats:sup>\u22125<\/jats:sup> m<jats:sup>\u22122<\/jats:sup> decrease in SVRI in another adjusted model (95% CI \u2212 36 to \u2212 162, <jats:italic>p<\/jats:italic> = 0.002, <jats:italic>n<\/jats:italic><jats:sub>pat<\/jats:sub> = 13). PCT had a stronger association to NA dose than HBP in a crude model but was not significantly associated to NA dose, MAP or SVRI in any time-adjusted model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Plasma HBP displayed a highly variable kinetic pattern during septic shock and was significantly associated to cardiovascular organ dysfunction severity over time.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40635-020-00338-8","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T18:03:52Z","timestamp":1599761032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Repeated measures of Heparin-binding protein (HBP) and procalcitonin during septic shock: biomarker kinetics and association with cardiovascular organ dysfunction"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-6673","authenticated-orcid":false,"given":"Jonas","family":"Tverring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Dankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"\u00c5kesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"issue":"1","key":"338_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ccc.2017.08.005","volume":"34","author":"JA Russell","year":"2018","unstructured":"Russell JA, Rush B, Boyd J (2018) Pathophysiology of septic shock. Crit Care Clin. 34(1):43\u201361","journal-title":"Crit Care Clin."},{"issue":"6","key":"338_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/joim.12604","volume":"281","author":"J Fisher","year":"2017","unstructured":"Fisher J, Linder A (2017) Heparin-binding protein: a key player in the pathophysiology of organ dysfunction in sepsis. J Intern Med. 281(6):562\u2013574","journal-title":"J Intern Med."},{"issue":"5","key":"338_CR3","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1182\/blood.V99.5.1785","volume":"99","author":"H Tapper","year":"2002","unstructured":"Tapper H, Karlsson A, Morgelin M, Flodgaard H, Herwald H (2002) Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles. Blood. 99(5):1785\u20131793","journal-title":"Blood."},{"issue":"10","key":"338_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/nm1001-1123","volume":"7","author":"N Gautam","year":"2001","unstructured":"Gautam N, Olofsson AM, Herwald H, Iversen LF, Lundgren-Akerlund E, Hedqvist P et al (2001) Heparin-binding protein (HBP\/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med. 7(10):1123\u20131127","journal-title":"Nat Med."},{"issue":"4","key":"338_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/jlb.51.4.316","volume":"51","author":"E Ostergaard","year":"1992","unstructured":"Ostergaard E, Flodgaard H (1992) A neutrophil-derived proteolytic inactive elastase homologue (hHBP) mediates reversible contraction of fibroblasts and endothelial cell monolayers and stimulates monocyte survival and thrombospondin secretion. J Leukoc Biol. 51(4):316\u2013323","journal-title":"J Leukoc Biol."},{"issue":"5","key":"338_CR6","first-page":"1414","volume":"43","author":"X Ruan","year":"2002","unstructured":"Ruan X, Chodosh J, Callegan MC, Booth MC, Lee TD, Kumar P et al (2002) Corneal expression of the inflammatory mediator CAP37. Invest Ophthalmol Vis Sci. 43(5):1414\u20131421","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"5","key":"338_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3892\/etm.2014.1939","volume":"8","author":"L Wang","year":"2014","unstructured":"Wang L, Liu Z, Dong Z, Pan J, Ma X (2014) Azurocidin-induced inhibition of oxygen metabolism in mitochondria is antagonized by heparin. Exp Ther Med. 8(5):1473\u20131478","journal-title":"Exp Ther Med."},{"issue":"1","key":"338_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40635-016-0104-3","volume":"4","author":"P Bentzer","year":"2016","unstructured":"Bentzer P, Fisher J, Kong HJ, Morgelin M, Boyd JH, Walley KR et al (2016) Heparin-binding protein is important for vascular leak in sepsis. Intensive Care Med Exp. 4(1):33","journal-title":"Intensive Care Med Exp."},{"issue":"7","key":"338_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1086\/605563","volume":"49","author":"A Linder","year":"2009","unstructured":"Linder A, Christensson B, Herwald H, Bjorck L, Akesson P (2009) Heparin-binding protein: an early marker of circulatory failure in sepsis. Clin Infect Dis. 49(7):1044\u20131050","journal-title":"Clin Infect Dis."},{"issue":"11","key":"338_CR10","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1097\/CCM.0000000000001265","volume":"43","author":"A Linder","year":"2015","unstructured":"Linder A, Arnold R, Boyd JH, Zindovic M, Zindovic I, Lange A et al (2015) Heparin-binding protein measurement improves the prediction of severe infection with organ dysfunction in the emergency department. Crit Care Med. 43(11):2378\u20132386","journal-title":"Crit Care Med."},{"key":"338_CR11","doi-asserted-by":"crossref","unstructured":"Kahn F, Tverring J, Mellhammar L, Wetterberg N, Blackberg A, Studahl E, et al. Heparin-binding protein as a prognostic biomarker of sepsis and disease severity at the emergency department. Shock. 2019.","DOI":"10.1097\/SHK.0000000000001332"},{"issue":"3","key":"338_CR12","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/cc11353","volume":"16","author":"A Linder","year":"2012","unstructured":"Linder A, Akesson P, Inghammar M, Treutiger CJ, Linner A, Sunden-Cullberg J (2012) Elevated plasma levels of heparin-binding protein in intensive care unit patients with severe sepsis and septic shock. Crit Care. 16(3):R90","journal-title":"Crit Care."},{"issue":"3","key":"338_CR13","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/cc12787","volume":"17","author":"P Schuetz","year":"2013","unstructured":"Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E (2013) Procalcitonin decrease over 72\u2009hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care. 17(3):R115","journal-title":"Crit Care."},{"issue":"8","key":"338_CR14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1097\/01.CCM.0000132904.35713.A7","volume":"32","author":"HB Nguyen","year":"2004","unstructured":"Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA et al (2004) Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 32(8):1637\u20131642","journal-title":"Crit Care Med."},{"issue":"5","key":"338_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 40(5):373\u2013383","journal-title":"J Chronic Dis."},{"issue":"8","key":"338_CR16","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 315(8):801\u2013810","journal-title":"JAMA."},{"issue":"2","key":"338_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1476-5381.2009.00433.x","volume":"159","author":"KL Becker","year":"2010","unstructured":"Becker KL, Snider R, Nylen ES (2010) Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 159(2):253\u2013264","journal-title":"Br J Pharmacol."},{"issue":"12","key":"338_CR18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al (2014) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 12(12):1495\u20131499","journal-title":"Int J Surg."},{"issue":"9","key":"338_CR19","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1097\/00003246-200209000-00023","volume":"30","author":"G Hoffmann","year":"2002","unstructured":"Hoffmann G, Czechowski M, Schloesser M, Schobersberger W (2002) Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med. 30(9):2091\u20132095","journal-title":"Crit Care Med."},{"issue":"3","key":"338_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/SHK.0000000000000862","volume":"48","author":"J Fisher","year":"2017","unstructured":"Fisher J, Russell JA, Bentzer P, Parsons D, Secchia S, Morgelin M et al (2017) Heparin-binding protein (HBP): a causative marker and potential target for heparin treatment of human sepsis-induced acute kidney injury. Shock. 48(3):313\u2013320","journal-title":"Shock."},{"issue":"1","key":"338_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13613-017-0330-1","volume":"7","author":"J Tverring","year":"2017","unstructured":"Tverring J, Vaara ST, Fisher J, Poukkanen M, Pettila V, Linder A et al (2017) Heparin-binding protein (HBP) improves prediction of sepsis-related acute kidney injury. Ann Intensive Care. 7(1):105","journal-title":"Ann Intensive Care."},{"issue":"20","key":"338_CR22","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z et al (2019) Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. Jama. 321(20):2003\u20132017","journal-title":"Jama."},{"issue":"8","key":"338_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.it.2010.05.006","volume":"31","author":"C Summers","year":"2010","unstructured":"Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER (2010) Neutrophil kinetics in health and disease. Trends Immunol. 31(8):318\u2013324","journal-title":"Trends Immunol."},{"issue":"8","key":"338_CR24","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.burns.2009.02.021","volume":"35","author":"J Johansson","year":"2009","unstructured":"Johansson J, Lindbom L, Herwald H, Sjoberg F (2009) Neutrophil-derived heparin binding protein--a mediator of increased vascular permeability after burns? Burns. 35(8):1185\u20131187","journal-title":"Burns."},{"issue":"8","key":"338_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221813","volume":"14","author":"L Samuelsson","year":"2019","unstructured":"Samuelsson L, Tyden J, Herwald H, Hultin M, Wallden J, Steinvall I et al (2019) Renal clearance of heparin-binding protein and elimination during renal replacement therapy: Studies in ICU patients and healthy volunteers. PLoS One. 14(8):e0221813","journal-title":"PLoS One."},{"issue":"4","key":"338_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00134-003-2121-4","volume":"30","author":"C Brun-Buisson","year":"2004","unstructured":"Brun-Buisson C, Meshaka P, Pinton P, Vallet B, Group ES (2004) EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 30(4):580\u2013588","journal-title":"Intensive Care Med."}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-020-00338-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-020-00338-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-020-00338-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T23:08:54Z","timestamp":1631228934000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-020-00338-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1186\/s40635-020-00338-8","relation":{},"ISSN":["2197-425X"],"issn-type":[{"value":"2197-425X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Regional Ethical Review Board at Lund University approved the study design in the year 2014 and 2016 (Dnr 2014\/741 and 2016\/271). Each participant or his\/her proxy gave written informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL and P\u00c5 are listed as inventors on a pending patent application on the use of HBP as a diagnostic tool in sepsis filed by Hansa Medical AB. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}